Zhitong Financial APP News, Chuangmei Pharmaceutical Co., Ltd. (02289) issued an announcement that as of the date of this announcement, potential buyers are conducting due diligence on the company. At the same time, potential buyers and Yao Chuanglong are negotiating the contents of a formal agreement.
Due to family planning and the timely and smooth implementation of the share Cooperation intention Agreement for potential buyers to gain control of the company, Yao Chuanglong plans to transfer his 14.75 million domestic shares (accounting for about 13.66% of the company's total issued share capital) to his spouse you Zeyan at a consideration of RMB 1 per share by December 31, 2021. If the share transfer is completed before December 31, 2021, the sales restrictions on possible transactions will be lifted next year, and the transaction may be carried out in 2022 in the following ways: Yao Chuanglong transfers his 11.0625 million domestic shares held at that time to potential buyers It also prompted you Zeyan to transfer her 14.75 million domestic shares and other domestic shares (about 13.24% of the company's total issued share capital) to potential buyers, instead of transferring domestic shares in two stages as disclosed in the announcement on October 21, 2021. Upon completion of the above transfer, Yao Chuanglong shall hold 33.1875 million shares (about 30.73% of the company's total issued share capital), and potential buyers shall hold 40.1125 million domestic shares (about 37.14% of the company's total issued share capital) in order to gain control of the company.
Upon completion of the share transfer, Yao Chuanglong and potential buyers will timely amend the above-mentioned matters in the share Cooperation intention Agreement or make an agreement in the formal agreement (as the case may be) by way of a supplementary agreement.
As of the date of this announcement, the parties have not entered into any agreement on a possible transaction.